Research programme: Nogo receptor decoy - ReNetX Bio

Drug Profile

Research programme: Nogo receptor decoy - ReNetX Bio

Alternative Names: NgR(310)ecto-Fc

Latest Information Update: 11 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yale University
  • Developer ReNetX Bio
  • Class Proteins
  • Mechanism of Action Myelin protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Spinal cord injuries; Stroke
  • Research Glaucoma

Most Recent Events

  • 10 Apr 2018 ReNetX Bio plans to submit IND to US FDA for a phase I/II trial for Spinal cord injuries
  • 18 Oct 2017 ReNetX Bio in-licenses patents related to nogo receptor decoy programme from Yale University (ReNetX Bio pipeline, October 2017)
  • 18 Oct 2017 ReNetX Bio plans a proof of concept clinical trial for Spinal cord injuries in 2020 (ReNetX Bio pipeline, October 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top